NeuroEndocrine Tumors Diagnostic and therapeutic challenges: Pancreatic NET Case ESMO preceptorship - Singapore

Similar documents
Case report. Kováčová Martina Comenius University in Bratislava Slovakia Faculty of medicine

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors

Grade 2 Ileum NET with liver and bone metastasis

Renal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland

Case Scenario 1. Discharge Summary

Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging

Antiangiogenics are effective treatments in NETs

Background. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.

Lab 14 Endocrine System

Section Activity Activity Description Details Reference(s)

Surgery for NET Challenges and specific aspects

Approach to a patient with hypercalcemia

GEP NEN. Personalised approach. Curative and Palliative Surgery. ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano April 2018

Parathyroid Disease Scenarios for the Practicing Clinician. Vijaya Chockalingam MD Faculty Endocrinologist Banner University Medical Center- Phoenix

An Unexpected Cause of Hypoglycemia

Presentation of Cases /Audience Voting/Panel/Discussion

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause

Surgical Therapy of GEP-NET: An Overview

A VIPER IN THE COURTYARD L A I L A ABUZA I D, M D

Autoimmune Pancreatitis: A Great Imitator

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS

Imaging of Neuroendocrine Metastases

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate

The PET-NET Study 2016 CNETS Grant Award

Hot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT

NET und NEC. Endoscopic and oncologic therapy

Clinical Approach to Hypercalcemia For the Primary Care Provider

Accepted Manuscript. Classical features of Zollinger-Ellison syndrome, in images. Ali Alshati, MD, Toufic Kachaamy, MD

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives

Case Report Pancreatic Aetiology for Massive Upper Gastrointestinal Haemorrhage in Pregnancy

Recent developments of oncology in neuroendocrine tumors (NETs)

Hypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance

Case(s): How to Deal with Mixed Response Giuseppe Procopio

Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors

Type 2 gastric neuroendocrine tumor: report of one case

Peptide Receptor Radionuclide Therapy (PRRT) of NET

Outcomes Report: Accountability Measures and Quality Improvements

HYPERCALCEMIA. Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences

Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer

Dr Claire Smith, Consultant Radiologist St James University Hospital Leeds

COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.

Pregnancy in the middle of adjuvant treatment of Her2 positive breast cancer

Ronald C. Walker, MD, Prof of Radiology Vanderbilt University Medical Center Nashville, TN. Ga-DOTATATE PET/CT imaging Initial Vanderbilt experience

B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.

NEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS. BY: Shifaa Qa qa

Strategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova

Index. Note: Page numbers of article titles are in boldface type.

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

Metastatic multiple endocrine neoplasia type 1: report of one case

What is Your Diagnosis?

Nuevas alternativas en el manejo de TNE avanzados

THERANOSTICS MOLEKULARE BILDGEBUNG MITTELS PET/CT

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

CASE REPORT AN UNCOMMON PRESENTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AT DISEASE PROGRESSION. Michael Mian, MD General Hospital of Bolzano

Addison's disease Neuroendocrine tumors Paraneoplastic syndromes

Oral Cavity. 1. Introduction. 1.1 General Information and Aetiology. 1.2 Diagnosis and Treatment

Metabolic Syndrome and Chronic Kidney Disease

LIVER. Question 1 ~ Anatomy. Answer 1 ~ Anatomy 1/5/2018. SEMCME Board Review January 11-12, 2017

Surgical Treatment of Hepatobiliary and Splenic Disorders

Komplette Mesokolische Exzision (CME) Ergebnisse und Ausblicke

An Overview of NETS. Richard R.P. Warner M.D

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies

Case Report Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog

MEDICAL MANAGEMENT OF METASTATIC GEP-NET

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC

Community Case. Saeed Awan R5

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ

What to do and not do before seeking surgical consultation for a patient with suspected pancreatic cancer

Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.

Commonly Encountered Neuro-Endocrine Tumors of the Gut

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID

Evaluation of Suspected Pancreatic Cancer

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

Update on Surgical Management of NETs

Case report Osteosarcoma of long bone metastatic to the pancreas-an unusual site of

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description

Routine Clinic Lab Studies

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description

Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.

Sandostatin LAR. Sandostatin LAR (octreotide acetate) Description

PANCREATIC NEUROENDOCRINE TUMOURS A

SARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY

Complex case Presentations

CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES

Lu 177-Dotatate (Lutathera) Therapy Information

SIRT in the Management of Metastatic Neuroendocrine Tumors

Pituitary, Parathyroid Pheochromocytomas & Paragangliomas: The 4 Ps of NETs

Pancreatic Adenocarcinoma: Everything You Need to Know From Cross-Sectional Imaging to Treatment

Potential conflicts of interest: None

Transcription:

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: Pancreatic NET Case presentation @ ESMO preceptorship - Singapore Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium

Mr AR Real story all facts are correct and real

AR - man born in 1941 Medical history 02/2001: diagnosis well differentiated NET of the pancreas body and tail with hypercalcemia no evidence of metastases PTH low Inoperable during laparotomy because of vessel invasion (city X) R/ octreotide & pamidronaat Later: alfa interferon 2004: referral to Leuven: because of local disease progression Laparotomy: extensive resection (pancreas, surrenal gland, spleen & lymphnodes) Histology: well differentiated NET; Ki67:15%; negative LN and negative resection margins (2 mm) No adjuvant treatment Postoperative normalisation of hypercalcemia

AR - man born in 1941 Medical history 2007 : Hypercalcemia till 14.1 mg/dl Vit D nl; PTH very low Decreased renal function Locoregional relapse with multiple levermetastases and abdominal lymphnodes Octreoscan: positive R/ start octreotide LAR 20mg q4w; later increase ot 30 mg q4w Hypercalcemia manageable 2008 : Tumorprogression and further increase of serum calcium AtrioVentricular block: 2nd degree stop octreotide 1/2008 to 06/2009 : 3x intrahepatic chemoembolisations (city X)

AR - man born in 1941 Medical history 2009 : Leuven Hypercalcemia frequent episodes till >14 mg/dl 25-OH-vitamin D : 20.2 µg/l (7.0-60.0) 1,85 PTH very low : < 0.1 ng/l (3.0-40.0) Hypercalcemia and hypofosfatemie in framework of HHM (humoral hypercalcemia of malignancy) caused by production of PTH-related peptide. Treated with intermittently diuretics; rehydratation; low dose biphosphonates ; a few times calcitonin and corticosteroids Decreased renal function Imaging: progression locoregional relapse with multiple levermetastases and abdominal lymphnodes Octreoscan: positive Exclusion for PRRT (Yttrium in Leuven)

Possibly scan AR - MAN BORN IN 1941

discussion

AR - man born in 1941 Medical history July 2009 : Start sunitinib 37.5 mg/day Good tolerance Fast normalisation of hypercalcemia Clear regression on imaging 12/2009 : Nefrotic syndrome with proteinuria -14 g/d - and increase in serum creatinine Kidney biopsy focal sclerosis compatible with secundary changes to sunitinib Sunitinib stopped. Proteinuria improved till 2-3 g/d

mg/dl Serum Calcium - 11/2007-12/ 2009

AR - man born in 1941 Medical history 02/2010-04/2010 acute coronary sydrome and ischemic cardiac decompensation, EF 50% 05/2010 : Relapse hypercalcemia Proteinuria persistent: 2-3 g/d R/intermittent including: rehydratation diuretics, corticosteroids, calcitonin, pamidronate

discussion

AR - man born in 1941 Medical history 30/08/2010 : Imaging: progessive disease and persistent, refractory hypercalcemia R/ Restart sunitinib 25 mg/d after extensive discussion and also at request of patient and family Fast normalisation of hypercalcemia 17/09/2010: acute detoriation of renal function NSTEMI stop sunitinib

mg/dl Evolution 01/2010 10/2010

AR - man born in 1941 Medical history 30/08/2010 : Imaging: progessive disease and persistent, refractory hypercalcemia R/ Restart sunitinib 25 mg/d after extensive discussion and also at request of patient and family 17/09/2010: acute renal failure, NSTEMI stop sunitinib Coronarography: Right coronary art.: slightly narrowed. Main coronary art.: no relevant abnormalities Left anterior descendens, circumflex & ramus intermedius: severe stenoses

AR - man born in 1941 Medical history 17/09/2010: acute renal failure, NSTEMI stop sunitinib Proteinuria persistent October/November 2010: Relapse Refractory Hypercalcemia Serum creatinine increase AngioMRI (total body): slight increase of tumor load

Serum calcium 08/2010-11/2010 mg/dl 16 14 Sunitinib (epidose 2) <------------------------> 12 10 8 6 Calcium Creatinine 4 2 0

discussion

AR - man born in 1941 Medical history 17/09/2010: acute renal failure, NSTEMI stop sunitinib Serum creatinine Proteinuria persistent October/November 2010: Relapse Refractory Hypercalcemia Serum creatinine increase AngioMRI (total body): slight increase of tumor load End november 2010: Start everolimus 10 mg/day

AR - man born in 1941 Medical history End november 2010: Start everolimus 10 mg/day January 2011: Calcium normalized Acute nose bleeding+++ with decrease in Hemoglobine till 6.2 g/dl, with secondary NSTEMI probably secondary to mucositis++ (everolimus related?) Stop everolimus early january

Serum Calcium 11/2010 03/2011 14 12 mg/dl Everolimus 10 mg <-------------------------------------------------------------> 10 8 6 4 calcium creatinine 2 0

discussion

AR - man born in 1941 Medical history End november 2010: Start everolimus 10 mg/day January 2011: Calcium normalized Acute nose bleeding+++ with decrease in Hemoglobine till 6.2 g/dl, with secondary NSTEMI probably secondary to mucositis++ (everolimus related?) Stop everolimus early january March 3, 2011 Hypercalcemia: 12,5 & 13,1 mg/dl Restart everolimus at a dose of 5 mg/day

Serum Calcium 11/2010 03/2011 14 12 10 8 6 4 2 0 mg/dl Everolimus 10 mg <-------------------------------------------------------------> Everolimus 5 mg <-------- calcium creatinine

Mr AR and his family are extremely grateful for progress in treatment options for PNET